Bristol-Myers Squibb Company ( (BMY) ) has released its Q4 earnings. Here is a breakdown of the information Bristol-Myers Squibb Company presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bristol Myers Squibb, a global biopharmaceutical company, specializes in developing innovative medicines for serious diseases, with a focus on sustained growth and long-term shareholder returns. In its latest earnings report for the fourth quarter and full year of 2024, Bristol Myers Squibb highlighted significant revenue growth driven by its Growth Portfolio, despite facing challenges from generic competition in its Legacy Portfolio. The company reported fourth-quarter revenues of $12.3 billion, an 8% increase, and full-year revenues of $48.3 billion, a 7% increase. Notably, new product launches and approvals in neuroscience and oncology, along with a strategic initiative targeting $2 billion in cost savings by 2027, underscored its commitment to innovation and efficiency. Looking ahead, Bristol Myers Squibb provided guidance for 2025, with an anticipated revenue of approximately $45.5 billion, driven by strategic expansions in its Growth Portfolio despite expected declines in the Legacy Portfolio. This outlook reflects the company’s strategic focus on maintaining a leading position in the biopharmaceutical industry.